Have a question for our experts to answer?
Submit it to our experts. We’d be happy to help.
Method development is the first real moment of truth in a bioanalytical project. It sets the trajectory for everything that follows, from validation to sample analysis to final reporting.Over the next 12 weeks, our subject matter experts will share practical insights, real-world examples, and regulatory perspectives showing you how to excel your method development.
Join the discussion on LinkedIn or check back to this page each week for fresh content and tools.
Have a question you’d like answered? Submit it to our experts. We’d be happy to help.
Method development is the first real moment of truth in a bioanalytical project. It sets the trajectory for everything that follows, from validation to sample analysis to final reporting.
And yet, one of the most common challenges we see is not technical. It is alignment.
Strong method development does not start in the lab. It starts with what the sponsor brings into the conversation.
A well-developed method is not just about sensitivity or selectivity. It is about fitness for purpose.
If the foundation is unclear, teams end up iterating, reworking, and losing time. In early development programs, that time matters.
The difference between a smooth program and a reactive one often comes down to the quality of inputs at the start.
What decisions will this data support? This sounds simple, but it drives everything:
Without this, method development becomes guesswork.
Basic characterization is critical:
Any previous observations helps the lab anticipate challenges early.
Where will this method be applied?
Matrix drives complexity. Tissue and microsampling require very different approaches than standard plasma work.
Even rough estimates are valuable:
This informs assay range and avoids rework when real samples arrive.
Availability and quality matter:
Delays here can stall development entirely.
Is this:
The level of rigor and documentation changes based on intended use.
Be explicit:
This helps labs allocate resources appropriately and avoid surprises.
Most issues we see are not capability gaps. They are communication gaps.
These lead to avoidable delays and rework.
The most successful programs share a common approach:
Method development is not a transactional step. It is a strategic one.
If you want speed, quality, and reliability downstream, invest the time upfront. The best bioanalytical methods are not just developed. They are built on clarity.
Looking for more information on method development?
Download the “Getting Method Development Right: What Bioanalytical Sponsors Must Bring to the Table” Infographic
An easy-to-use reference that highlights seven key elements
Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.
Method development rarely fails because of technical limitations. It fails because expectations were never clearly defined.
And the issue often starts early, even if it is not recognized until much later.
At Alturas, we consistently see that misalignment at this stage does not stop progress. It redirects it.
When expectations are unclear, teams keep moving. But they move in the wrong direction.
Time is spent optimizing performance that may not be required. Complexity is introduced without purpose. And what should be structured iteration becomes reactive troubleshooting.
We recently saw a program where an aggressive LLOQ target was set without a clear link to study decisions. The result was weeks of added development time with no impact on the outcome of the study.
In early-stage programs, that time matters.
At Alturas, we approach method development as a decision-making phase, not just execution.
Define success early, align on trade-offs, and accept iteration as part of the process.
If method development feels unpredictable, it is rarely the science. It is the absence of clearly defined expectations.
Clarity does not eliminate iteration. It makes iteration productive.
Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.
Most method development challenges do not come from complexity. They come from where the process starts.
Too often, method development begins at the instrument instead of at the problem.
Starting in the wrong place compounds inefficiency. Teams waste time optimizing parameters before confirming method objectives.
At Alturas, we start with fundamentals, confirm feasibility early, and build complexity only when needed.
Where you start determines how efficient method development becomes. Start with the problem, not the instrument.
Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.
Most method development problems are not surprises.
They are predictable.
The issue is not that they occur. It is when they are identified.
Late-stage issues are expensive to fix.
Repeating experiments to address these issues can cost your program extra time and money.
At Alturas, we prioritize simplest extraction possible, matrix effects evaluation and matrix stability checks to prevent downstream rework.
The fastest programs are not the ones that fix problems quickly.
They are the ones that prevent them.
Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.
Most transferred methods do not break during initial development. They break when assumptions meet a new laboratory environment.
Transferred methods should always be critically reviewed prior to implementation in the receiving laboratory. It is crucial to determine whether the method is built on good bioanalytical fundamentals or if it is standing on poor decisions and inefficient techniques.
A method that was validated in one laboratory is not automatically ready for seamless execution in another.
Small differences can create significant variability causing accuracy and precision problems with the method.
This is where we consistently see bioanalytical programs quietly lose time, create rework, and introduce unnecessary risk.
Method transfer is not an administrative handoff. It is a scientific reassessment of robustness, reproducibility, and fitness-for-purpose under new operating conditions.
As a CRO, we often see transferred methods arrive with assumptions from our clients that need to be challenged:
Sometimes they do.
Sometimes they do not.
And the cost of discovering those gaps late compounds the complexity of the method development impacting validation timelines and sample analysis.
The strongest transfers happen when sponsors and CRO teams approach the process collaboratively and scientifically from the beginning.
That means aligning early on:
Strong method transfer is not about proving the original method worked.
It is about proving the method remains reliable, reproducible, and defensible in the new laboratory environment where critical study decisions and regulatory data generation occur.
That difference matters more than most teams realize.
Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.
Study samples expose assay weaknesses that can’t be tested in method development using purchased matrices spiked with the target compound.
This is where otherwise promising bioanalytical methods begin to struggle.
And what looked robust during method development suddenly becomes far more complex under real study conditions.
As a CRO, we see this most often when methods are developed around idealized assumptions instead of operational reality.
Study samples introduce variables that cannot be ignored:
The strongest bioanalytical methods are not designed only for analytical performance.
They are designed for real-world execution.
That means considering how the method will behave across the actual study lifecycle, not just under controlled development conditions.
Because once study samples arrive, the cost of discovering gaps increases quickly.
Strong sample bioanalysis starts long before the first sample is analyzed.
Submit Your Method Development Questions to Our Scientific Experts
Throughout this series, our team will be answering real questions in short-form videos and commentary. No fluff — just real insights from the field. Have something you’ve always wanted explained more clearly? Curious how these concepts apply to your specific challenge? Now’s the time to ask.
Getting Method Development Right: What Bioanalytical Sponsors Must Bring to the Table
Avoiding the Pitfalls of Method Development Before They Cost You
Checklist: Method Development Diligence to Prepare for Study Samples
Chad has over 24 years of related experience as an analytical scientist with over 20 years focused on bioanalysis at Alturas Analytics. Chad is responsible for supervision of the analytical method development team in supporting method validations and sample analysis and Study Director/Principal Investigator on GLP and clinical studies, providing technical oversight to clients across all therapeutic areas.
"*" indicates required fields
